Applied Therapeutics, Inc. Research and Development Expense
Applied Therapeutics, Inc. reported Research and Development Expense of $9.60 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2025-11-13
- Applied Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $9.60M, a 35.25% decline year-over-year.
- Applied Therapeutics, Inc. research and development expense for the quarter ending 2025-06-30 was $9.92M, a 0.81% decline year-over-year.
- Applied Therapeutics, Inc. research and development expense for the quarter ending 2025-03-31 was $7.84M, a 35.85% decline year-over-year.
- Applied Therapeutics, Inc. research and development expense for the quarter ending 2024-12-31 was $11.70M, a 23.58% decline year-over-year.
- Applied Therapeutics, Inc. research and development expense for fiscal 2024 was $48.74M, a 9.57% decline from fiscal 2023.
- Applied Therapeutics, Inc. research and development expense for fiscal 2023 was $53.91M, a 3.11% decline from fiscal 2022.
- Applied Therapeutics, Inc. research and development expense for fiscal 2022 was $55.63M, a 11.09% decline from fiscal 2021.
- Applied Therapeutics, Inc. research and development expense for fiscal 2021 was $62.57M, a 1.27% increase from fiscal 2020.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2025-09-30 | $9.60M 10-Q · filed 2025-11-13 | $19.52M derived: sum of 2 quarters · filed 2025-11-13 | $27.36M 10-Q · filed 2025-11-13 | $39.06M derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | $9.92M 10-Q · filed 2025-08-13 | $17.76M 10-Q · filed 2025-08-13 | $29.45M derived: sum of 3 quarters · filed 2025-08-13 | $44.28M derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-03-31 | $7.84M 10-Q · filed 2025-05-14 | $19.53M derived: sum of 2 quarters · filed 2025-05-14 | $34.36M derived: sum of 3 quarters · filed 2025-11-13 | $44.36M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-12-31 | $11.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $26.52M derived: sum of 2 quarters · filed 2025-11-13 | $36.53M derived: sum of 3 quarters · filed 2025-11-13 | $48.74M 10-K · filed 2025-04-15 |
| 2024-09-30 | $14.83M 10-Q · filed 2025-11-13 | $24.83M derived: sum of 2 quarters · filed 2025-11-13 | $37.05M 10-Q · filed 2025-11-13 | $52.35M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $10.00M 10-Q · filed 2025-08-13 | $22.22M 10-Q · filed 2025-08-13 | $37.52M derived: sum of 3 quarters · filed 2025-08-13 | $48.31M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $12.22M 10-Q · filed 2024-05-09 | $27.52M derived: sum of 2 quarters · filed 2025-04-15 | $38.30M derived: sum of 3 quarters · filed 2025-04-15 | $50.19M derived: sum of 4 quarters · filed 2025-04-15 |
| 2023-12-31 | $15.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $26.09M derived: sum of 2 quarters · filed 2025-04-15 | $37.97M derived: sum of 3 quarters · filed 2025-04-15 | $53.91M 10-K · filed 2025-04-15 |
| 2023-09-30 | $10.79M 10-Q · filed 2024-11-07 | $22.67M derived: sum of 2 quarters · filed 2024-11-07 | $38.60M 10-Q · filed 2024-11-07 | $50.70M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $11.88M 10-Q · filed 2024-08-07 | $27.82M 10-Q · filed 2024-08-07 | $39.91M derived: sum of 3 quarters · filed 2024-08-07 | $53.03M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $15.94M 10-Q · filed 2024-05-09 | $28.03M derived: sum of 2 quarters · filed 2024-05-09 | $41.14M derived: sum of 3 quarters · filed 2024-05-09 | $56.54M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $12.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $25.21M derived: sum of 2 quarters · filed 2024-03-06 | $40.60M derived: sum of 3 quarters · filed 2024-03-06 | $55.63M 10-K · filed 2024-03-06 |
| 2022-09-30 | $13.12M 10-Q · filed 2023-11-09 | $28.51M derived: sum of 2 quarters · filed 2023-11-09 | $43.54M 10-Q · filed 2023-11-09 | $59.27M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $15.40M 10-Q · filed 2023-08-10 | $30.43M 10-Q · filed 2023-08-10 | $46.15M derived: sum of 3 quarters · filed 2023-08-10 | $63.75M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $15.03M 10-Q · filed 2023-05-11 | $30.75M derived: sum of 2 quarters · filed 2023-05-11 | $48.35M derived: sum of 3 quarters · filed 2023-05-11 | $63.15M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $15.72M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $33.32M derived: sum of 2 quarters · filed 2023-03-23 | $48.12M derived: sum of 3 quarters · filed 2023-03-23 | $62.57M 10-K · filed 2023-03-23 |
| 2021-09-30 | $17.60M 10-Q · filed 2022-11-09 | $32.40M derived: sum of 2 quarters · filed 2022-11-09 | $46.85M 10-Q · filed 2022-11-09 | $60.66M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $14.80M 10-Q · filed 2022-08-12 | $29.25M 10-Q · filed 2022-08-12 | $43.06M derived: sum of 3 quarters · filed 2022-08-12 | $63.01M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $14.45M 10-Q · filed 2022-05-12 | $28.26M derived: sum of 2 quarters · filed 2022-05-12 | $48.21M derived: sum of 3 quarters · filed 2022-05-12 | $68.97M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $13.81M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $33.76M derived: sum of 2 quarters · filed 2022-03-10 | $54.52M derived: sum of 3 quarters · filed 2022-03-10 | $61.79M 10-K · filed 2022-03-10 |
| 2020-09-30 | $19.95M 10-Q · filed 2021-11-12 | $40.70M derived: sum of 2 quarters · filed 2021-11-12 | $47.97M 10-Q · filed 2021-11-12 | $61.74M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $20.76M 10-Q · filed 2021-08-12 | $28.03M 10-Q · filed 2021-08-12 | $41.80M derived: sum of 3 quarters · filed 2021-08-12 | $49.25M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $7.27M 10-Q · filed 2021-05-11 | $21.04M derived: sum of 2 quarters · filed 2021-05-11 | $28.49M derived: sum of 3 quarters · filed 2021-05-11 | $32.75M derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | $13.77M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $21.22M derived: sum of 2 quarters · filed 2021-03-18 | $25.48M derived: sum of 3 quarters · filed 2021-03-18 | $32.35M 10-K · filed 2021-03-18 |
| 2019-09-30 | $7.45M 10-Q · filed 2020-11-12 | $11.71M derived: sum of 2 quarters · filed 2020-11-12 | $18.58M 10-Q · filed 2020-11-12 | $23.94M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $4.25M 10-Q · filed 2020-08-11 | $11.13M 10-Q · filed 2020-08-11 | $16.49M derived: sum of 3 quarters · filed 2020-08-11 | $19.21M derived: sum of 4 quarters · filed 2020-08-11 |
| 2019-03-31 | $6.87M 10-Q · filed 2020-05-11 | $12.23M derived: sum of 2 quarters · filed 2020-05-11 | $14.96M derived: sum of 3 quarters · filed 2020-05-11 | $16.90M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $5.36M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $8.09M derived: sum of 2 quarters · filed 2020-03-13 | $10.02M derived: sum of 3 quarters · filed 2020-03-13 | $11.47M 10-K · filed 2020-03-13 |
| 2018-09-30 | $2.73M 10-Q · filed 2019-11-13 | $4.66M derived: sum of 2 quarters · filed 2019-11-13 | $6.11M 10-Q · filed 2019-11-13 | |
| 2018-06-30 | $1.94M 10-Q · filed 2019-08-12 | $3.38M 10-Q · filed 2019-08-12 | ||
| 2018-03-31 | $1.45M 10-Q · filed 2019-06-21 |